U.S. Draft Executive Order “More Bark Than Bite”: Will Chinese Innovative-Drug BD Deals Still Benefit Long-Term?China Finance Tech in China3SBio, Biotech, CSPC Pharmaceutical Group, FDA, GSK, Hebo Pharmaceuticals, Hengrui, Pharmaceuticals September 12, 2025
China’s Innovative Drug Sector is Exploding: Here’s Why Investors Are BuzzingChina Finance Tech in China3SBio, Biotechnology, Bohai Securities, Changshan Pharma, China Securities, Cinda Securities, CSPC Pharmaceutical Group, Everbright Securities, Haichen Pharmaceutical, Healthcare, Huafu Securities, Innovative Drugs, Joincare Pharmaceutical, Lianhe Chemical Technology, Luoxin Pharmaceutical, Medicilon, NMPA, Pfizer, Pharmaceuticals, Shenyang Sansheng, Sunshine Guojian, Xiangcai Securities June 9, 2025
Innovent Biologics (Xìndá Shēngwù 信达生物) Stock Jumps 18% on Promising IBI363 Lung Cancer Data, Igniting the Innovative Drug SectorChina Finance3SBio, Biotech, CSPC Pharmaceutical Group, Innovation, Innovent Biologics, Pharmaceuticals June 4, 2025
